[{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mission Raises $15m and Expands its Relationship with Pfizer","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mission and AbbVie deal in Alzheimer\u2019s and Parkinson Reaches Next Milestone","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Mission Therapeutics Awarded Follow-On Therapeutic Pipeline Programme Grant From MJFF","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mission Therapeutics Authorised to Initiate First Clinical Trial for Lead DUB Program, MTX652, in Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Nephrology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mission Therapeutics Successfully Completes First Clinical Assessment for Lead DUB Program, MTX652","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mission Therapeutics Announces US FDA Approval to Initiate Phase II Clinical Trial of its Lead Asset MTX652 in Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Nephrology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mission Therapeutics Granted MHRA Clinical Trial Authorisation (CTA) for MTX325 for the Treatment of Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"$5.2 million","upfrontCash":"Undisclosed","newsHeadline":"Mission Therapeutics Awarded $5.2M from Michael J. Fox Foundation and Parkinson's UK","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Mission Therapeutics
The funding aims to support the company's investigattional product MTX325 brain-penetrant USP30 inhibitor. It is being evaluated in early-stage studies for the treatment of Parkinson's disease.
MTX652 is a potent and selective compound designed to improve mitochondrial quality and function by enhancing mitophagy through inhibition of USP30 enzyme. It is being evaluated for the treatment of acute kidney injury (AKI) following cardiac surgery.
MTX325 is a USP30 inhibitor small molecule drug candidate, which is currently being evaluated in clinical trial studies with patients for the treatment of parkinson's disease.
MTX652 potently and specifically inhibits USP30 with the aim of enabling appropriate degradation of dysfunctional mitochondria to preserve overall mitochondrial quality and improve cellular health.
Mission has developed MTX652 to inhibit USP30 with the aim to enable appropriate degradation of dysfunctional mitochondria to preserve and improve cellular health. Mission is also investigating the potential of USP30 inhibitors to treat these diseases.
The research grant will support testing of Mission’s lead CNS-penetrant USP30 DUB inhibitors in an in vivo model of Familial Parkinson’s Disease (PD), as well as ongoing preclinical development towards candidate selection.
Under the terms of the agreement, first announced in 2018, Mission and AbbVie are collaborating to identify novel DUB targets and discover associated inhibitor compounds for neurodegenerative diseases.